Evaluation of Strontium-۸۹ in palliative treatment of widespread and painful bone metastases due to breast and prostate cancer [Persian]
محل انتشار: مجله پزشکی هسته ای ایران، دوره: 8، شماره: 1
سال انتشار: 1379
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 135
فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
این مقاله در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IRJNM-8-1_010
تاریخ نمایه سازی: 7 تیر 1401
چکیده مقاله:
Treatment of bone metastases comprises over ۱۰% of the workload of a radiation-oncology center. Bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. A good palliative treatment must be complete, free from side effects and fast; Thus we decided to evaluate Strontium-۸۹ (۸۹Sr) effectivity for palliation of breast and prostate cancer bone metastases in relation to above factors. The use of ۸۹Sr radionuclide therapy started on ۱۹۹۲ in radiation-oncology department of Cancer Institute. Until early ۱۹۹۹, ۹۱ patients with bone metstases have been treated for pain relief in our department with ۴ mCi of ۸۹Sr. Of these, ۸۰ were breast and prostate metastatic cancers. ۳۵ patients came back for follow-up and were completely evaluated. Response was seen in ۶۵% of patients (Complete response in ۴۰% and partial response in ۲۵%). Side effects were negligible, and quality of life of the responding patients significantly increased. There was no significant relationship between the type of primary cancer or patient age and response. In conclusion, treatment of metastatic bone cancer from prostate and breast primaries in our department was effective, with a relatively high rate of response and no serious side effects.
کلیدواژه ها:
نویسندگان
Farhad Ghadiri
Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Peiman Haddad
Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Jahangir Mehdifar
Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Hojjat Zeraati
Department of Biostatistics, Faculty of Health, Tehran University of Medical Sciences, Tehran, Iran